The stock of Summit Therapeutics Inc (SMMT) has gone up by 5.36% for the week, with a -1.26% drop in the past month and a 4.38% rise in the past quarter. The volatility ratio for the week is 6.74%, and the volatility levels for the past 30 days are 7.14% for SMMT. The simple moving average for the past 20 days is 5.05% for SMMT’s stock, with a 42.06% simple moving average for the past 200 days.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
The stock has a 36-month beta value of -1.15. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SMMT is 82.98M, and at present, short sellers hold a 27.59% of that float. On May 01, 2024, the average trading volume of SMMT was 2.12M shares.
SMMT) stock’s latest price update
The stock price of Summit Therapeutics Inc (NASDAQ: SMMT) has surged by 1.29 when compared to previous closing price of 3.88, but the company has seen a 5.36% gain in its stock price over the last five trading sessions. Business Wire reported 2024-04-24 that MIAMI–(BUSINESS WIRE)—- $SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available on our website. About Ivon.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Stifel repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to Stifel is $8 based on the research report published on March 26, 2024 of the current year 2024.
SMMT Trading at -3.03% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.71% of loss for the given period.
Volatility was left at 7.14%, however, over the last 30 days, the volatility rate increased by 6.74%, as shares surge +2.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.49% lower at present.
During the last 5 trading sessions, SMMT rose by +5.36%, which changed the moving average for the period of 200-days by +83.64% in comparison to the 20-day moving average, which settled at $3.74. In addition, Summit Therapeutics Inc saw 50.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SMMT starting from Zanganeh Mahkam, who purchase 54,321 shares at the price of $3.72 back on Mar 27 ’24. After this action, Zanganeh Mahkam now owns 24,923,800 shares of Summit Therapeutics Inc, valued at $201,874 using the latest closing price.
Zanganeh Mahkam, the Chief Executive Officer of Summit Therapeutics Inc, purchase 26,000 shares at $3.72 during a trade that took place back on Mar 27 ’24, which means that Zanganeh Mahkam is holding 520,814 shares at $96,720 based on the most recent closing price.
Stock Fundamentals for SMMT
Current profitability levels for the company are sitting at:
- 1925.8 for the present operating margin
- -7.72 for the gross margin
The net margin for Summit Therapeutics Inc stands at -7035.23. The total capital return value is set at 2.48. Equity return is now at value -601.88, with -141.84 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.72. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is 27.49.
Currently, EBITDA for the company is -87.69 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 11881.69. The receivables turnover for the company is 0.28for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.30.
Conclusion
To sum up, Summit Therapeutics Inc (SMMT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
